This document provides information about the "CNS Clinical Trials" conference taking place on September 16-17, 2010 in London. The conference will examine strategies for successful CNS drug development and overcoming challenges in clinical trial design, management, and recruitment. Key topics will include novel cognitive assessment methods, advances in neuroimaging, adaptive trial design, and the use of biomarkers to demonstrate early drug effects in CNS trials. Speakers will include representatives from pharmaceutical and biotechnology companies as well as academic institutions. Attendees will gain insights on improving various aspects of CNS clinical trials from development through regulatory approval. The conference also provides sponsorship and exhibition opportunities for companies to promote their products and services.
The document announces the 5th Annual Pharmacovigilance Conference to be held from March 17-19, 2010 in London. It will discuss implementing best practices in drug safety and surveillance. Key topics include evaluation of risk mitigation strategies, classification of adverse drug reactions, pharmacovigilance in clinical trials, proposals from the EU Commission's "Pharma Package", and developing training programs for global pharmacovigilance systems. The conference will provide insights and best practices in pharmacovigilance from leaders in the industry.
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...Business Turku
This presentation provides an overview of Orion's new strategy from a midsize pharmaceutical perspective. It discusses Orion's business segments and key financial metrics. It then summarizes major pharmaceutical industry trends, including aging populations, advances in technology, and increased regulation. Finally, it outlines Orion's strategic growth target of €1.5 billion in net sales by 2025 and focus areas to achieve this, such as delivering its late-stage portfolio, building its pipeline, maximizing the value of existing assets, and exploring new partnerships and technologies.
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...Business Turku
This document provides an overview of PerkinElmer, a company focused on diagnostics, life sciences, food, and applied markets. It discusses their mission of innovating for a healthier world, with over 80 years of innovations including a COVID-19 PCR kit launched in 2020. The company's diagnostics segment focuses on reproductive health, immunoassays, and applied genomics. PerkinElmer has global capabilities across molecular diagnostics, imaging, automation, and more. It is pursuing growth in areas like single-cell analysis, therapeutics, digital solutions, and decentralized testing. The company's strategy focuses on detection, decentralization, and digitization to drive profitable growth.
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
This document provides information about the "Vaccine Research & Innovation 2010" conference taking place on September 2-3, 2010 in London. The conference will explore opportunities in vaccine research and development and feature key speakers from companies such as Novartis Vaccines, Merck, and Intercell. Attendees will gain insights into topics like overcoming challenges in cancer vaccine development, evaluating immune responses to combination vaccines, and implementing strategies for manufacturing conjugate vaccines. The conference is designed to share successful strategies and innovative technologies for developing more effective vaccines.
HealthBIO 2021,_The InFlames Flagship_Timo VeromaaBusiness Turku
The document provides an overview of the InFLAMES Research Flagship program at the University of Turku in Finland. Some key points:
- InFLAMES brings together over 300 researchers from the University of Turku and Åbo Akademi University focused on immunology research.
- The program aims to make breakthroughs in drug development, diagnostics, and precision immune medicine through discovery, testing, and utilization of novel immunological findings.
- It provides researchers access to high-quality open access research infrastructure facilities like the Turku Bioscience Centre, Turku PET Centre, and Auria Biobank to support both academic and industry collaborations.
- Measuring impact, InFLAMES
HealthBIO 2020_Tero Piispanen_Turku Science ParkBusiness Turku
- 12 new biotech companies were created in Finland between June 2019 and October 2020, the smallest number in years, due to the COVID-19 pandemic.
- Total Finnish health tech export was €2.4 billion in 2019, with China as the largest export market thanks to strong demand for diagnostic equipment.
- Several Finnish biotech companies had successful clinical trials, funding rounds, partnerships and FDA/EMA approvals in areas such as oncology, neurology, rare diseases and COVID-19 vaccines.
The East of England is a major center for medical technologies and healthcare companies, contributing £500m annually to the economy. It is home to over 400 healthcare companies and 5,000 expert employees. The region contributes 25% of the UK's total R&D spending, three times the national average, and is a global leader in areas like drug delivery, medical materials, diagnostics and nanotechnology due to collaboration between its universities, hospitals, and industry partners. This document provides information on organizations and facilities supporting medical innovation through research, product development, and commercialization in the East of England region.
The document announces the 5th Annual Pharmacovigilance Conference to be held from March 17-19, 2010 in London. It will discuss implementing best practices in drug safety and surveillance. Key topics include evaluation of risk mitigation strategies, classification of adverse drug reactions, pharmacovigilance in clinical trials, proposals from the EU Commission's "Pharma Package", and developing training programs for global pharmacovigilance systems. The conference will provide insights and best practices in pharmacovigilance from leaders in the industry.
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...Business Turku
This presentation provides an overview of Orion's new strategy from a midsize pharmaceutical perspective. It discusses Orion's business segments and key financial metrics. It then summarizes major pharmaceutical industry trends, including aging populations, advances in technology, and increased regulation. Finally, it outlines Orion's strategic growth target of €1.5 billion in net sales by 2025 and focus areas to achieve this, such as delivering its late-stage portfolio, building its pipeline, maximizing the value of existing assets, and exploring new partnerships and technologies.
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...Business Turku
This document provides an overview of PerkinElmer, a company focused on diagnostics, life sciences, food, and applied markets. It discusses their mission of innovating for a healthier world, with over 80 years of innovations including a COVID-19 PCR kit launched in 2020. The company's diagnostics segment focuses on reproductive health, immunoassays, and applied genomics. PerkinElmer has global capabilities across molecular diagnostics, imaging, automation, and more. It is pursuing growth in areas like single-cell analysis, therapeutics, digital solutions, and decentralized testing. The company's strategy focuses on detection, decentralization, and digitization to drive profitable growth.
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
This document provides information about the "Vaccine Research & Innovation 2010" conference taking place on September 2-3, 2010 in London. The conference will explore opportunities in vaccine research and development and feature key speakers from companies such as Novartis Vaccines, Merck, and Intercell. Attendees will gain insights into topics like overcoming challenges in cancer vaccine development, evaluating immune responses to combination vaccines, and implementing strategies for manufacturing conjugate vaccines. The conference is designed to share successful strategies and innovative technologies for developing more effective vaccines.
HealthBIO 2021,_The InFlames Flagship_Timo VeromaaBusiness Turku
The document provides an overview of the InFLAMES Research Flagship program at the University of Turku in Finland. Some key points:
- InFLAMES brings together over 300 researchers from the University of Turku and Åbo Akademi University focused on immunology research.
- The program aims to make breakthroughs in drug development, diagnostics, and precision immune medicine through discovery, testing, and utilization of novel immunological findings.
- It provides researchers access to high-quality open access research infrastructure facilities like the Turku Bioscience Centre, Turku PET Centre, and Auria Biobank to support both academic and industry collaborations.
- Measuring impact, InFLAMES
HealthBIO 2020_Tero Piispanen_Turku Science ParkBusiness Turku
- 12 new biotech companies were created in Finland between June 2019 and October 2020, the smallest number in years, due to the COVID-19 pandemic.
- Total Finnish health tech export was €2.4 billion in 2019, with China as the largest export market thanks to strong demand for diagnostic equipment.
- Several Finnish biotech companies had successful clinical trials, funding rounds, partnerships and FDA/EMA approvals in areas such as oncology, neurology, rare diseases and COVID-19 vaccines.
The East of England is a major center for medical technologies and healthcare companies, contributing £500m annually to the economy. It is home to over 400 healthcare companies and 5,000 expert employees. The region contributes 25% of the UK's total R&D spending, three times the national average, and is a global leader in areas like drug delivery, medical materials, diagnostics and nanotechnology due to collaboration between its universities, hospitals, and industry partners. This document provides information on organizations and facilities supporting medical innovation through research, product development, and commercialization in the East of England region.
HealthBIO 2020 Aino Kalervo Tilt BiotherapeuticsBusiness Turku
TILT Biotherapeutics develops oncolytic immunotherapies to enable T cell therapies and checkpoint inhibitors. Its lead product TILT-123, a cytokine-armed oncolytic virus, has shown 100% cure rates in vivo and is currently in a Phase 1 clinical trial in Europe. TILT aims to explore licensing agreements to support the commercialization of its pipeline of oncolytic viruses, which have the potential to make T cell therapies and checkpoint inhibitors more effective for cancer treatment. The company has a strong international team and funding to advance its clinical programs through 2022.
This document provides information about the 3rd Annual Conference on Drug Discovery Chemistry hosted by SMi Group. The conference will take place on March 18-19, 2019 in London, UK, with a half-day workshop on March 20. Key speakers will discuss topics such as novel drug modalities, targeting difficult proteins, using artificial intelligence in drug discovery, and optimizing drug discovery techniques. Attendees can learn about recent advances, network with industry leaders, and explore strategic partnerships. Discounts are available for early registration.
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen Business Turku
Finnish biotech year 2020-2021 saw the creation of 12 new companies in areas like drug development, diagnostics, and medtech. The health tech industry in Finland continues to grow with record exports in 2020. Several Finnish companies had successes including clinical trial progress, partnerships, and facility expansions. However, venture capital investment in Finnish life sciences remains low compared to Europe, with Finnish companies often only receiving seed funding.
HealthBIO 2021_Cancer I/O Translating immuno-oncology into health actions_Jer...Business Turku
This document provides a summary of an introduction to cancer immuno-oncology. It discusses utilizing the immune system to kill cancer cells and the increasing uptake of immuno-oncology drugs. It outlines the goals of the Cancer IO Office to facilitate immuno-oncology uptake through strategic foresight, societal discussion, and Finnish immuno-oncology research. The document describes the Cancer IO Office's themes of immuno-oncology in society, research, and healthcare which include developing 3D cancer culture models, utilizing real-world data to identify super responders, and analyzing immuno-oncology uptake in Finnish hospitals.
How PerkinElmer became world's market leader?, Marika KaseBusiness Turku
PerkinElmer has become the world leader in newborn screening through long-term investments, partnerships focusing on customer needs, and expanding their product range and geographic coverage. They have screened over 522 million babies cumulatively. Currently, PerkinElmer screens 37 million babies annually and helps save around 24,000 babies per year from various treatable conditions. PerkinElmer provides a complete solution for newborn screening including sample collection, processing, measuring, data processing and consulting services to support screening programs around the world.
The document discusses imaging agent innovation challenges in France and the role of AVIESAN in addressing them. AVIESAN coordinates national research efforts, provides infrastructure like imaging platforms, and unites academic and industry actors through dedicated processes and clusters to translate imaging agents from discovery to clinical use. This is done by identifying unmet medical needs, supporting early clinical trials, and facilitating partnerships between researchers, SMEs, diagnostic and pharmaceutical companies.
The document summarizes HealthBIO 2021, Finland's largest annual life science event taking place on its 15th year and bringing together over 200 companies and academics. It also provides details about FIB (Finnish Bioindustries), the biotechnology industry association established in 1997 to promote networking and information sharing in the life science sector. FIB helps commercialize new biotechnology areas and supports national and international cooperation for legislation related to the field. Finally, it outlines Forendo Pharma's focus on women's health through development of HSD17B enzyme inhibitors for conditions like endometriosis and PCOS, with one drug entering phase 2 trials in 2022 and another starting phase 1.
Global cancer nanomedicine market outlook 2022Rajesh Sarma
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview & Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design & Strategy
Cancer Nanomedicine as Diagnostic & Therapeutics Tool
Global Cancer Nanomedicine Market Overview & Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Download Global cancer nanomedicine market outlook 2022KuicK Research
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
The document discusses how physics research has led to advancements in medicine and biology. Specifically, it mentions how particle physics technologies like accelerators, detectors, and computing have been used for medical diagnosis and cancer treatment. It then describes CERN's efforts to facilitate knowledge transfer from physics to healthcare, including the CERN Medical Applications Office, Medical Applications Steering Group, and International Strategy Committee which work to identify and support relevant initiatives.
This document outlines a roadmap for developing molecular diagnostics in the Netherlands. It discusses the need to integrate biomarker discovery with diagnostic test development and clinical application. The goal is to define a framework that facilitates moving candidate biomarkers through validation and regulatory approval to reimbursed clinical use. This will help address unmet medical needs through improved personalized healthcare.
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
The document is a report on the state of the UK drug discovery industry in 2019. It finds that most small and medium enterprises in the industry are service and supply companies, employing fewer than 20 people. The majority of drug development assets held by UK companies are focused on cancer, anti-infectives, and central nervous system disorders. Artificial intelligence and cell and gene therapies are seen as promising but in need of further validation and data. The report recommends that the government increase funding support and that the Medicines Discovery Catapult continue connecting companies, providing access to datasets and technologies, and helping to validate new models like complex cell models.
The document discusses developing inexpensive solutions for monitoring C-reactive protein (CRP) levels using printing technology. VTT Technical Research Centre of Finland, University of Turku, and Åbo Akademi University are working with an industrial partner, Orion Diagnostica Oy, to research and develop affordable CRP sensors printed on paper or plastic substrates. The goal is to create easy-to-use and low-cost testing alternatives to standard CRP immunoassays through printing methods like coating and using detection techniques such as capacitive sensors.
PEGS Europe Protein & Antibody Engineering Summit 2014 AgendaNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
2013-10-23 DTL Next Generation Life Sciences Event, UtrechtAlain van Gool
This document summarizes a case study on identifying microRNA targets for miRNA-based cancer therapeutics. Researchers from Radboud University Medical Center, TNO, and InteRNA collaborated using various omics technologies. They screened 1120 miRNAs to identify those that inhibit epithelial-to-mesenchymal transition and cancer cell invasion/metastasis. Proteomics and transcriptomics were used to validate miRNA targets, and CyTargetLink integrated the multi-omics data. The collaboration aimed to improve understanding of miRNA effects on cancer metastasis through integrated systems biology approaches.
Crossroads: U.S. Medical Device Regulation vs. Innovation
The U.S. medical device industry is at a regulatory and potentially economic crossroad as the FDA continues to refine its 510(k) regulatory submission requirements and guidelines. Medical device manufacturers have been urging the FDA and Congress to expedite new product review processes to spur innovation and bring new medical technologies to market faster. However, supporters of stricter FDA regulations claim that a faster regulatory review process causes unsafe devices to enter the market.
As a result of numerous exchanges between both sides of the issue, CDRH (FDA) recently issued multiple updates to its initiatives for the 510(k) approval process. To shed light on key changes, we obtained the support of the office of Dr. Jeffrey Shuren MD JD, Director of CDRH and Dr. John Smith MD JD, of Hogan Lovells, a prominent international law firm with a medical regulatory specialty, on their interpretations of the 510(k) regulatory guidelines and the impact these guidelines will have on medical device manufacturers.
Listen to the Dr. John Smith podcast interview here:
http://youtu.be/iHVpwwXi7dY
The MarkeTech Group
502 Mace Blvd.
Davis, CA 95618
http://www.themarketechgroup.com
This document provides an overview of nanomedicine and outlines several key areas. It begins by defining nanomedicine and its applications in areas like diagnostics, therapeutics, and future technologies. The introduction then summarizes some of the major achievements in the field over the past 15 years. The remainder of the document contains 8 articles that discuss topics like the design of nanomedicines, their interactions with the immune system, applications for diseases like cancer, diabetes, stroke and atherosclerosis, and the importance of patient stratification. It highlights how controlling properties like size, shape, surface characteristics and mechanics can improve drug delivery and addresses challenges to further clinical translation of nanomedicines.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
This is a conference about drug discovery and drug development. G protein-coupled receptor (GPCR) and protein kinases are the biggest drug targets in medicine. Around half of all drugs, for whatever disease, work by interacting with different GPCRs and kinases.
The document summarizes an upcoming conference on biobanking in the Americas from June 7-9, 2011 in Boston. It will bring together experts from biobanks, pharmaceutical companies, biotech firms, and regulatory agencies to discuss strategic approaches to biosample management and using biobanks to enable next-generation drug discovery and personalized medicine. Speakers will provide practical knowledge on new biobanking models, address ethical and legal challenges, and explore how to leverage biospecimen resources to support biomarker research. Attendees will learn best practices for biorepository management and implementation, applications of genome sequencing, and strategies for building biomarker discovery pipelines. The conference aims to facilitate networking and enable confident decision making through benchmarking against
HealthBIO 2020 Aino Kalervo Tilt BiotherapeuticsBusiness Turku
TILT Biotherapeutics develops oncolytic immunotherapies to enable T cell therapies and checkpoint inhibitors. Its lead product TILT-123, a cytokine-armed oncolytic virus, has shown 100% cure rates in vivo and is currently in a Phase 1 clinical trial in Europe. TILT aims to explore licensing agreements to support the commercialization of its pipeline of oncolytic viruses, which have the potential to make T cell therapies and checkpoint inhibitors more effective for cancer treatment. The company has a strong international team and funding to advance its clinical programs through 2022.
This document provides information about the 3rd Annual Conference on Drug Discovery Chemistry hosted by SMi Group. The conference will take place on March 18-19, 2019 in London, UK, with a half-day workshop on March 20. Key speakers will discuss topics such as novel drug modalities, targeting difficult proteins, using artificial intelligence in drug discovery, and optimizing drug discovery techniques. Attendees can learn about recent advances, network with industry leaders, and explore strategic partnerships. Discounts are available for early registration.
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen Business Turku
Finnish biotech year 2020-2021 saw the creation of 12 new companies in areas like drug development, diagnostics, and medtech. The health tech industry in Finland continues to grow with record exports in 2020. Several Finnish companies had successes including clinical trial progress, partnerships, and facility expansions. However, venture capital investment in Finnish life sciences remains low compared to Europe, with Finnish companies often only receiving seed funding.
HealthBIO 2021_Cancer I/O Translating immuno-oncology into health actions_Jer...Business Turku
This document provides a summary of an introduction to cancer immuno-oncology. It discusses utilizing the immune system to kill cancer cells and the increasing uptake of immuno-oncology drugs. It outlines the goals of the Cancer IO Office to facilitate immuno-oncology uptake through strategic foresight, societal discussion, and Finnish immuno-oncology research. The document describes the Cancer IO Office's themes of immuno-oncology in society, research, and healthcare which include developing 3D cancer culture models, utilizing real-world data to identify super responders, and analyzing immuno-oncology uptake in Finnish hospitals.
How PerkinElmer became world's market leader?, Marika KaseBusiness Turku
PerkinElmer has become the world leader in newborn screening through long-term investments, partnerships focusing on customer needs, and expanding their product range and geographic coverage. They have screened over 522 million babies cumulatively. Currently, PerkinElmer screens 37 million babies annually and helps save around 24,000 babies per year from various treatable conditions. PerkinElmer provides a complete solution for newborn screening including sample collection, processing, measuring, data processing and consulting services to support screening programs around the world.
The document discusses imaging agent innovation challenges in France and the role of AVIESAN in addressing them. AVIESAN coordinates national research efforts, provides infrastructure like imaging platforms, and unites academic and industry actors through dedicated processes and clusters to translate imaging agents from discovery to clinical use. This is done by identifying unmet medical needs, supporting early clinical trials, and facilitating partnerships between researchers, SMEs, diagnostic and pharmaceutical companies.
The document summarizes HealthBIO 2021, Finland's largest annual life science event taking place on its 15th year and bringing together over 200 companies and academics. It also provides details about FIB (Finnish Bioindustries), the biotechnology industry association established in 1997 to promote networking and information sharing in the life science sector. FIB helps commercialize new biotechnology areas and supports national and international cooperation for legislation related to the field. Finally, it outlines Forendo Pharma's focus on women's health through development of HSD17B enzyme inhibitors for conditions like endometriosis and PCOS, with one drug entering phase 2 trials in 2022 and another starting phase 1.
Global cancer nanomedicine market outlook 2022Rajesh Sarma
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview & Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design & Strategy
Cancer Nanomedicine as Diagnostic & Therapeutics Tool
Global Cancer Nanomedicine Market Overview & Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Download Global cancer nanomedicine market outlook 2022KuicK Research
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
The document discusses how physics research has led to advancements in medicine and biology. Specifically, it mentions how particle physics technologies like accelerators, detectors, and computing have been used for medical diagnosis and cancer treatment. It then describes CERN's efforts to facilitate knowledge transfer from physics to healthcare, including the CERN Medical Applications Office, Medical Applications Steering Group, and International Strategy Committee which work to identify and support relevant initiatives.
This document outlines a roadmap for developing molecular diagnostics in the Netherlands. It discusses the need to integrate biomarker discovery with diagnostic test development and clinical application. The goal is to define a framework that facilitates moving candidate biomarkers through validation and regulatory approval to reimbursed clinical use. This will help address unmet medical needs through improved personalized healthcare.
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
The document is a report on the state of the UK drug discovery industry in 2019. It finds that most small and medium enterprises in the industry are service and supply companies, employing fewer than 20 people. The majority of drug development assets held by UK companies are focused on cancer, anti-infectives, and central nervous system disorders. Artificial intelligence and cell and gene therapies are seen as promising but in need of further validation and data. The report recommends that the government increase funding support and that the Medicines Discovery Catapult continue connecting companies, providing access to datasets and technologies, and helping to validate new models like complex cell models.
The document discusses developing inexpensive solutions for monitoring C-reactive protein (CRP) levels using printing technology. VTT Technical Research Centre of Finland, University of Turku, and Åbo Akademi University are working with an industrial partner, Orion Diagnostica Oy, to research and develop affordable CRP sensors printed on paper or plastic substrates. The goal is to create easy-to-use and low-cost testing alternatives to standard CRP immunoassays through printing methods like coating and using detection techniques such as capacitive sensors.
PEGS Europe Protein & Antibody Engineering Summit 2014 AgendaNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
2013-10-23 DTL Next Generation Life Sciences Event, UtrechtAlain van Gool
This document summarizes a case study on identifying microRNA targets for miRNA-based cancer therapeutics. Researchers from Radboud University Medical Center, TNO, and InteRNA collaborated using various omics technologies. They screened 1120 miRNAs to identify those that inhibit epithelial-to-mesenchymal transition and cancer cell invasion/metastasis. Proteomics and transcriptomics were used to validate miRNA targets, and CyTargetLink integrated the multi-omics data. The collaboration aimed to improve understanding of miRNA effects on cancer metastasis through integrated systems biology approaches.
Crossroads: U.S. Medical Device Regulation vs. Innovation
The U.S. medical device industry is at a regulatory and potentially economic crossroad as the FDA continues to refine its 510(k) regulatory submission requirements and guidelines. Medical device manufacturers have been urging the FDA and Congress to expedite new product review processes to spur innovation and bring new medical technologies to market faster. However, supporters of stricter FDA regulations claim that a faster regulatory review process causes unsafe devices to enter the market.
As a result of numerous exchanges between both sides of the issue, CDRH (FDA) recently issued multiple updates to its initiatives for the 510(k) approval process. To shed light on key changes, we obtained the support of the office of Dr. Jeffrey Shuren MD JD, Director of CDRH and Dr. John Smith MD JD, of Hogan Lovells, a prominent international law firm with a medical regulatory specialty, on their interpretations of the 510(k) regulatory guidelines and the impact these guidelines will have on medical device manufacturers.
Listen to the Dr. John Smith podcast interview here:
http://youtu.be/iHVpwwXi7dY
The MarkeTech Group
502 Mace Blvd.
Davis, CA 95618
http://www.themarketechgroup.com
This document provides an overview of nanomedicine and outlines several key areas. It begins by defining nanomedicine and its applications in areas like diagnostics, therapeutics, and future technologies. The introduction then summarizes some of the major achievements in the field over the past 15 years. The remainder of the document contains 8 articles that discuss topics like the design of nanomedicines, their interactions with the immune system, applications for diseases like cancer, diabetes, stroke and atherosclerosis, and the importance of patient stratification. It highlights how controlling properties like size, shape, surface characteristics and mechanics can improve drug delivery and addresses challenges to further clinical translation of nanomedicines.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
This is a conference about drug discovery and drug development. G protein-coupled receptor (GPCR) and protein kinases are the biggest drug targets in medicine. Around half of all drugs, for whatever disease, work by interacting with different GPCRs and kinases.
The document summarizes an upcoming conference on biobanking in the Americas from June 7-9, 2011 in Boston. It will bring together experts from biobanks, pharmaceutical companies, biotech firms, and regulatory agencies to discuss strategic approaches to biosample management and using biobanks to enable next-generation drug discovery and personalized medicine. Speakers will provide practical knowledge on new biobanking models, address ethical and legal challenges, and explore how to leverage biospecimen resources to support biomarker research. Attendees will learn best practices for biorepository management and implementation, applications of genome sequencing, and strategies for building biomarker discovery pipelines. The conference aims to facilitate networking and enable confident decision making through benchmarking against
Email: Fax: +44(0) 20 7336 6100
Address: City: US Office:
Tel: +1 646 781 4485
Postcode: Country: Fax: +1 646 781 4489
Tel: Fax: Payment details
Special dietary requirements: Vegetarian: Yes/No Payment must be received in full prior to the conference. Please indicate how you would like to pay:
Signature: Date: Invoice: Please send an invoice to my company
Credit Card: Please debit my credit card (details below)
Payment details Visa/Mastercard/Amex/
Clinical Trial Logistics & Supply (2011) FbFateja
This document provides information about an upcoming clinical trial logistics and supply conference to be held in London on September 29-30, 2011. It lists key speakers from various pharmaceutical companies that will discuss topics like predictive drug supply modelling, bioequivalence studies, drug pooling strategies, quality assurance, and managing clinical trials in Eastern Europe. The document also provides details about sponsoring, exhibiting, and submitting poster presentations at the conference.
The document provides information about the 5th Annual Recombinant Antibodies conference taking place from January 17-19, 2012 in London. It will feature presentations and workshops on advances in bispecific antibodies, next-generation monoclonal antibodies, and antibody translation. Key speakers will represent companies such as Roche, Novartis, MedImmune. Workshop topics will include antibody drug conjugates. The conference aims to provide networking opportunities and insights into improving antibody potency, engineering, development, and applications for cancer, inflammatory diseases, and more.
Pharma IQ is announcing its 2011 clinical event series providing platforms for biotech and pharma professionals to initiate relationships and discuss challenges. The series includes 11 events focused on topics like oncology clinical development, clinical outsourcing, data standardization, clinical supply, and bioequivalence. The events will bring together senior industry experts through presentations and discussions to address issues like clinical trial design, data management, and regulatory requirements. Pharma IQ has over 40 years of experience organizing conferences and aims to provide a global platform to share knowledge and solutions.
Email: Cancellation terms: Cancellations must be made in writing at least 28 days before the conference
date to receive a full refund. Cancellations received between 14-28 days carry a 50% cancellation fee.
Special Dietary Requirements: Cancellations received less than 14 days before the event date are not eligible for a refund, but a
substitute delegate is welcome. Visiongain
This document provides information about the 6th Annual Pharmacovigilance Conference taking place on March 16-17, 2011 in London. The conference will discuss the latest developments in pharmacovigilance, drug safety, and risk management. It will feature keynote speakers from organizations like Pfizer, Abbott Laboratories, and Novartis. Sessions over the two days will cover topics like benefit-risk assessments, signal detection methodologies, pharmacovigilance during clinical trials, and the transition between pre- and post-marketing safety. The conference is aimed at professionals in fields like pharmacovigilance, drug development, clinical safety, and regulatory affairs.
This document provides an agenda for the "Aesthetics and Anti-Ageing" conference taking place on May 11-12, 2011 in London, UK. The conference will explore new developments in anti-aging therapies and latest technological advancements in aesthetic surgeries. Over the two days, keynote speakers will discuss topics such as changing market demands, innovations in facial rejuvenation surgeries, cosmeceuticals, fat stem cells, new technologies for delivering anti-aging agents to the skin, challenging surgical problems, platelet rich plasma, sports medicine, and more. The event is aimed at professionals in fields like pharmaceuticals, biotechnology, dermatology, anti-aging medicine, and aesthetic medicine.
The document discusses challenges and opportunities in the development of biosimilars. It provides perspectives from several industry experts on the top hurdle being a lack of clarity around intellectual property and marketing strategies as well as high development costs. The experts note that developing the necessary skill sets around quality by design, analytics, and clinical trial design is key to overcoming hurdles in developing biosimilars safely and effectively.
This document provides information about an upcoming conference on single-use bioreactors being held in London on November 1-2, 2012. The conference will feature speakers from pharmaceutical and biotech companies as well as equipment suppliers discussing topics such as using single-use bioreactors to increase flexibility, reduce costs and speed up research and development. Attendees will learn about case studies on scaling up production with disposable technology and accelerating cell culture development. The conference offers sponsorship and exhibition opportunities for companies to promote their services and products.
This document provides information about the 7th Annual Pharmacovigilance conference to be held on January 30-31, 2012 in London. The conference will discuss current pharmacovigilance regulations and strategies to improve drug safety, with key speakers from major pharmaceutical companies. Topics will include pharmacovigilance throughout a drug's lifecycle, risk management, safety surveillance, and new EU regulations. Attendees will gain insights on evaluating safety signals and benefit-risk assessments to increase drug safety.
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
This document discusses the importance and various applications of artificial intelligence in the pharmaceutical industry. It begins with an introduction from Dr. Ruchi Tiwari on the uses of AI in R&D, drug development, diagnosis, disease prevention, epidemic prediction, remote monitoring, manufacturing, and marketing. The rest of the document provides more details on each of these areas, including examples of companies using AI for drug discovery, clinical trials, adherence monitoring, and data analysis. It also discusses challenges to AI adoption in pharma such as unfamiliarity, lack of infrastructure, and unstructured data formats. The overall message is that AI has great potential to improve efficiency and outcomes across the pharmaceutical industry.
5 Best Companies in Digital Pathology Market, March 2023insightscare
TissueGnostics GmbH provides streamlined solutions for both biomedical imaging and image analysis through its tissue cytometers. Founded by Dr. Rupert Ecker based on his experience in microscopy during his PhD, TissueGnostics aims to advance research on cells and tissues through precision automation. The company develops its own software and works with partners to provide open platforms like TissueFAXS and COLUBRIS Tissue Cytometer with AI. Through collaborative projects, TissueGnostics continues innovating to address diverse questions in tissue cytometry while maintaining high standards for research and clinical applications.
This document provides information about the 4th Annual Biomarkers conference taking place on December 1-2, 2011 in London. The conference will cover biomarkers from discovery through clinical trials and safety. Key speakers will discuss regulatory perspectives, novel biomarker targets, how biomarkers can accelerate clinical development, and more. Attendees will learn about improvements in biomarker technologies and analyses of biomarkers' role in drug development. Poster presentations are encouraged. The global biomarkers market was estimated at $13.5 billion in 2010 and is predicted to reach $33.3 billion by 2015, driving growth in the industry.
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Dr. Nick Thomas 17:00 - 17:30 Closing Remarks & Networking Drinks
Investigator, Molecular Discovery Research Principal Scientist
Glax
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Moderator: John Shah 17:00 Close
Investigator, Molecular Discovery Research Conference Producer
GlaxoSmithKline
This interactive workshop will provide a comprehensive overview of label-free cell-based
This document provides information about an upcoming biobanking conference to take place on March 10-11, 2011 in London. It lists key speakers from companies like AstraZeneca, Bayer, and Sanofi-Aventis who will discuss topics like sample storage, biomarker discovery, and stem cell banking. The document also notes the growing market for biobanking and its importance for medical research. Sponsoring companies and media partners promoting the conference are also listed.
This document provides information about an upcoming conference on pre-filled syringes. It outlines the conference details including dates, location, key speakers from companies like Merck Serono and AstraZeneca. It also lists media partners, sponsors, and exhibitors. The document discusses the growing market for pre-filled syringes and challenges in the industry. It promotes the conference as a chance to learn about new developments, network, and address issues like drug compatibility and manufacturing processes. A pre-conference workshop on legal issues is also advertised.
This document is an announcement for the Biobanking Americas conference to be held from November 9-11, 2010 in Boston. The conference will bring together experts in biobanking including scientists, regulators, and researchers to discuss practical knowledge and strategic advice on biobanking models and frameworks. Key topics will include best practices for biobank resources, challenges in biorepository management, applications of genome sequencing, the future of biobanks, regulation, ethics, investment, and humanization of drug discovery. Speakers will provide insights into tissue and data bioprospecting, quality management, and benchmarking biobanking practices. The conference is aimed at VPs, directors, and managers of biobanks, tissue banks
The 4th Annual Contract Manufacturing conference will be held on December 13-14, 2010 in London. The conference will provide strategies and case studies on implementing Quality by Design (QbD) and Process Analytical Technology (PAT) to improve contract manufacturing relationships. Speakers from pharmaceutical companies like AstraZeneca, Novartis, and Amylin will discuss best practices for technology transfer, analytical methods validation, and managing contract manufacturing organizations throughout a product's lifecycle. The conference aims to help attendees maximize outsourcing opportunities and choose the right CMO partners.
The document is an invitation to the "Anti-Counterfeiting Americas" conference on November 8-9, 2010 in Boston. The conference will provide insights into issues related to securing the pharmaceutical supply chain and tracking technologies. Key topics will include tackling counterfeit drugs, improving distribution integrity, and collaboration against counterfeiting. Attendees will gain an understanding of supply chain challenges and investment potential in pharmaceutical logistics. The conference will feature speakers from organizations focused on supply chain security and counterfeit drug prevention.
The document summarizes the 7th Annual Biosimilars conference to be held from October 5-7, 2010 in London. The conference will discuss strategies for developing biosimilars and biobetters, including overcoming regulatory barriers and gaining market access. Over the three days, speakers will address topics such as the competitive landscape in major markets, the impact of healthcare reform on global development, and developing long-acting biologics. Attendees will include those from pharmaceutical, biotechnology, and regulatory organizations seeking to maximize opportunities in this growing industry segment.
9th Annual Pricing And Reimbursement Conferencejaayboy69
The document summarizes the 9th Annual Pricing and Reimbursement conference taking place from September 27-29, 2010 in London. It will feature keynote speakers from pharmaceutical companies, health technology assessment organizations, and consulting firms discussing practical solutions for pricing and reimbursement decisions. Attendees will gain insights into strategies for sustaining market share in a global recession, pricing for emerging markets, healthcare reform impacts, and risk management planning.
1. CNS Clinical Trials
Optimising development, management and recruitment for clinical trials in CNS
16th - 17th September 2010, BSG Conference Centre, London, UK BOOK NOW!
Key Speakers
Dr Erik Buntinx, Managing Director and Chief Scientific Officer, PharmaNeuroBoost
Dr Samuel Agus, Global Medical Affairs Director, Neurology, Solvay Pharmaceuticals Marketing and Licensing
Dr Stig Johan Wiklund, Statistical Science Director, AstraZeneca R&D
Dr Fabrizio Gasparini, Sr Research Investigator, Novartis Institutes for BioMedical Research
Dr Mark Tricklebank Director, Lilly Centre for Cognitive Neuroscience, Eli Lilly and Co
Dr Karl Herholz Director, Wolfson Molecular Imaging Centre/ Professor of Clinical Neuroscience,
University of Manchester
Professor Elaine Rankin, Medical Oncology, University of Dundee
Professor Alan M Palmer, Chief Scientific Officer, MS Therapeutics
Gaynor Anders Vice President Global Operations, MMG
Professor Mehdi Adineh, Scientific Director Diagnostic Imaging Core Laboratory, American College of Radiology
Dr. Michael G. Palfreyman, Head, Translational R&D, ChemDiv, Executive Program Director,
Senior Scientific Advisor, EnVivo Pharmaceuticals
Associate Sponsors
Driving the Industry Forward | www.futurepharmaus.com Organised By
Media Partners
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/cns-trials
2. Conference Introduction
CNS Clinical Trials
16th - 17th September 2010, London, UK
CNS is one of the largest and fastest growing therapeutic areas of the Associate Sponsors:
pharmaceutical market. The ageing of the baby-boom generation combined
with new and emerging treatments for neurodegenerative disorders, ACR Image Metrix, an imaging contract research organization (CRO)
including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, located in the American College of Radiology Clinical Research
will lead to further expansion of the neurodegenerative therapies market. Center in Philadelphia, applies imaging techniques to improve
(Source: Visiongain - World Neurodegenerative Diseases Market 2009 -2024) the efficiency of drug and medical device development programs. The world-class team of
radiologists and imaging scientists, at ACR Image Metrix, work with pharmaceutical, biotech
Dear Colleague, and medical device companies to integrate the appropriate imaging technologies, modalities
and clinical design techniques into their imaging studies. ACR Image Metrix has years of
t Visiongain’s CNS Clinical Trials conference you will examine the strategies offering
A experience utilizing state-of-the-art technologies to provide a complete line of imaging
the greatest potential for success in CNS drug development, and understand the specific services from site qualification and training, study initiation, image management, reader
challenges currently faced by developers in this market. In order to enhance productivity studies and much more.
in this field, there has been an increased awareness of the need to align clinical and For further information please visit: www.acr-imagemetrix.net
preclinical research to facilitate rapid development of new CNS drug therapies. Medical
imaging is increasingly being used as a surrogate endpoint or biomarker of drug efficacy ERT is a provider of technology and services to the pharmaceutical,
in all phases of CNS trials, enabling CNS developers to make more timely decisions. biotechnology and medical device industries. The Company is a market
leader in providing centralized core-diagnostic electrocardiographic
s part of this 2-day event, leading industry and academic authorities will address how
A (ECG) technology and services to evaluate cardiac safety in clinical development. Further,
to balance risk and how attrition can be reduced to increase the chances of success in ERT’s ePRO Solutions™ provide a simple, immediate conduit to the Sponsor’s most valuable
CNS clinical trials. Participants will look at overcoming some of the hurdles arising in asset – the patient. This phone based system captures throughout the Complete Patient
designing, managing and recruiting for CNS clinical trials, and examine the tools and Experience – from Recruiting and Screening, Assessments and Diaries through to Safety and
technologies to best enhance clinical development. Suicidality Monitoring. ERT harnesses internet and telecommunications technology and services
to streamline the clinical trials process by enabling its customers to automate the collection,
By attending this conference you will: analysis and distribution of clinical data in all phases of clinical development.
• Examine novel approaches for assessing cognitive function For further information please visit: www.ERT.com
• Explore the latest advances in neuroimaging Media Partners:
• Develop effective methods for improved patient recruitment and retention PharmiWeb.com is the leading industry-sponsored portal for
• Understand statistical thinking for designing adaptive trials the pharmaceutical sector. Supported by most of the leading
pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features,
• Review Good Clinical Practice GCP guidelines events listings and international jobs to industry professionals across Europe and the US.
• Address the regulatory challenges for CNS drug approval For further information please email: corporate@pharmiweb.com
• Utilise biomarkers for Proof of Concept in CNS clinical trials
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD.
• mprove trial outcomes through increased communication, ethical consent and
I It is based and located in Warsaw, Poland. Biotechnology World was
patient care founded in 2007 to provide the world’s biotech and pharma information and market to
• mplement translational methods to bridge the gap between pre-clinical and clinical
I make it universally accessible and useful for scientific and business processes. Its first step
to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will
CNS trials allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers
• Be part of a major networking opportunity companies completed internet public relations, publication and marketing solutions. One of
the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector
I look forward to meeting you at the conference in Europe to global biotechnology, pharmaceutical and life science activities.
Best regards For further information please visit: www.biotechnology-europe.com
Driving the Industry Forward | www.futurepharmaus.com
Future Pharmaceuticals has forged powerful relationships with key
industry leaders to provide a platform for successful brand recognition,
and for senior decision-makers to have the means to procure and plan implementation
Andrea Charles strategies based on the topics covered. Positioned to be an authoritative resource within top
Head of Conferences pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine
is geared to create a deep penetration into a highly targeted and responsive audience, bridging
the gap between the industries’ top issues and the solutions top-tier vendors can provide.
For further information please visit: www.futurepharmaus.com
Target Audience: InPharm is the online platform for exclusive pharmaceutical news,
• Pharmaceutical and biotech companies comment, contracts, services, jobs and events and is home to
• Clinical research organisations InPharmjobs.com, Pharmafile and Pharmafocus.
• Regulatory agencies/ associations
For further information please visit: www.In-Pharm.com
Who will be there? Pharma Connections Worldwide® is the leading professional
Senior VPs, VPs, Chief Scientific Officers, Directors, Heads and business networking website focused in the Pharmaceutical,
Managers of: Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for
• CNS Trials delivery of premiere content coupled with the right clientele in order to facilitate business
• Clinical Trials development opportunities among industry professionals responsible for making key
• Clinical Research & Development decisions in a global marketplace.
• Clinical Operations For further information please visit: www.pharmaconnections.com
• CNS
• CNS Clinical Biomarker Group
• Clinical Pharmacology
• Neurobiology
• Neuromedical Oncology Sponsorship and exhibition opportunities:
• Neurology/ Neuroscience Research This event offers a unique opportunity to meet and do business with some of the key
• Psychiatry
• Psychology players in the pharmaceutical and biotech industries. If you have a service or product to
• CNS Ageing Research promote, you can do so at this event by:
• Dementia
• Imaging/ Neuroimaging • Hosting a networking drinks reception
• Movement Disorders • Taking an exhibition space at the conference
• CNS Global Marketing & Medicine
• Preclinical R&D • Advertising in the delegate documentation pack
• Translational Medicine • Providing branded bags, pens, gifts, etc.
• Biostatistics
• Experimental Therapeutics If you would like more information on the range of sponsorship or exhibition possibilities
• Clinical Technology for visiongain's CNS Clinical Trials Conference, please contact us:
• Outcomes Research
• Regulatory Affairs Christopher Clegg, +44 (0)20 7549 9964
• Product Development christopher.clegg@visiongainglobal.com
• Neurologists
3. Day 1
CNS Clinical Trials
Thursday 16th September 2010
09:30 Registration and refreshments 14:30 mGluR5 Allosteric Antagonists: Preclinical profile
and choice of therapeutic indication
• haracterization of mGluR5 antagonist in preclinical paradigm
C
10:00 Opening address from the chair
• Validation of objective markers for monitoring drug action
• se of preclinical profiling and proof-of-concept clinical trials to
U
10:10 The discovery and development of CNS medicines select therapeutic indications for full development
• rogress in CNS medicines research
P Dr Fabrizio Gasparini
• Market landscape Sr Research Investigator
Novartis Institutes for BioMedical Research
• The challenges for CNS R&D
• Future prospects
15:10 Suicidality: Ensuring quality in mandated
Professor Alan M Palmer
Chief Scientific Officert
prospective monitoring
MS Therapeutics • verview of the Columbia-Suicide Severity Rating Scale (C-SSRS)
O
• otential pitfalls with collection of suicidality monitoring data
P
10:50 Addressing specific challenges arising in the clinical • C-SSRS - electronically modeling and reproducing the optimal
e
human interview
trials of neuroprotective agents
• C-SSRS – meeting the goals of excellent science and clinical care
e
• C-SSRS – a clinical trial case study
e
11:30 Morning refreshments Dr John Greist
Distinguished Senior Scientist, Madison Institute of Medicine
Clinical Professor of Psychiatry, University of Wisconsin
11:50 Clinical value of accelerated anti-depressant effect School of Medicine and Public Health
• Lag time of antidepressants: an unmet medical need
• arly and Sustained Full Response: A new FDA approved
E
efficacy paradigm 15:50 Afternoon refreshments
• harmacological considerations to induce accelerated
P
antidepressant effect
16:10 CNS clinical trials beyond registration
• reatment adherence in relation to an antidepressant with an
T
• rials beyond registration a tool for assessing a drug in real-life setting
T
accelerated effect
• ypes of post-registration studies, goals, deliverables and methods
T
Dr Erik Buntinx
Managing Director and Chief Scientific Officer • When should trials beyond registration begin?
PharmaNeuroBoost • ife cycle management and drug safety- 2 sides for the same coin
L
• ho initiates investigator-initiated-trials and what is their purpose
W
12:30 Considerations for design and statistical analysis Dr Samuel Agus
of CNS trials Global Medical Affairs Director, Neurology
Solvay Pharmaceuticals Marketing and Licensing
• Analysis and design for disease modification
• Missing data issues
• Adaptive design issues when applied in CNS trials 16:50 Closing remarks from the chair
Dr Stig Johan Wiklund
Statistical Science Director
AstraZeneca R&D
17:00 Networking drinks
13:10 Networking Lunch Take your discussions further and build new
relationships in a relaxed and informal setting.
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2010
4. Day 2
CNS Clinical Trials
Friday 17th September 2010
09:30 Registration and refreshments 13:10 Networking Lunch
14.10 Use of biomarkers for demonstrating CNS effects of
10:00 Opening address from the chair
drugs early in clinical development
• Using animal PK/PD data to set dose range finding in Phase 1
10:10 Bridging the gap between pre-clinical and • Use of QEEG to demonstrate CNS activity
clinical CNS trials
• Computer measures of cognition
• Translational assays of cognition • Evoked potentials to demonstrate clinical potential
• Animal models of cognitive impairment Dr. Michael G. Palfreyman
• Use of preclinical biomarkers to enhance assay translation Head, Translational R&D, ChemDiv
Executive Program Director, Senior Scientific Advisor, EnVivo
• linical testing of preclinical hypotheses
C Pharmaceuticals
Dr Mark Tricklebank
Director, Lilly Centre for Cognitive Neuroscience 14:50 Recruiting strategies for Huntington’s Disease
Eli Lilly and Co clinical trials
• he importance of identifying unique barriers to participation in HD
T
clinical trials
10:50 Reducing the gap between preclinical PK/PD and
• rass-roots social marketing for HD trials can speed enrollment:
G
CNS clinical trials a pilot study
• dding value to the discovery of CNS active drugs through the application
A
• reating the HD trial participant as VIP is a cost-effective approach.
T
of mechanistic PK/PD principles
Dr LaVonne Veatch Goodman
• nderstanding the key drivers of in-vivo pharmacological effects and
U
Co-founder
ensuring they are prominent in the lead optimisation paradigm Huntington’s Disease Drug Works (HDDW)
• stablishing the link between blood concentration, receptor occupancy
E
and drug efficacy 15:30 Afternoon refreshments
11:30 Morning refreshments 15:50 Patient recruitment and retention strategies for
CNS clinical trials
• atient population insights that need to be considered in designing
P
11:50 Novel imaging approaches in clinical trials and the recruitment and retention programs for CNS trials
role of an imaging CRO • trategies for overcoming global CNS patient recruitment challenges
S
• ovel Imaging Approaches including Structural, Functional and Molecular
N
• pdates on evolving trends in patient recruitment and retention methodologies
U
in CNS Drug Discovery including PET, DTI, fMRI and vCT. • llustrative case studies of effective tactics
I
• maging Drug Actions Including Neuroreceptor Mapping
I
Gaynor Anders
Vice President Global Operations
• he role of an Imaging CRO in Managing an Imaging Clinical Trial
T
MMG
Professor Mehdi Adineh
Scientific Director Diagnostic Imaging Core Laboratory 16.30 Successful strategies for accelerating
American College of Radiology patient recruitment
• Preparing for successful enrolment
12:30 Utilising PET imaging biomarkers • The ideal set-up
• Dementia: glucose metabolism, amyloid tracers, acetylcholine analogues • Avoiding the pitfalls for a pharma-driven trial
• Parkinson’s disease: dopamine synthesis & storage capacity • Enlisting support from patients
• Psychiatric disorders: dopamine & serotonin receptor occupancy Professor Elaine Rankin
Medical Oncology
• Brain tumours: progression and infiltration
University of Dundee
• Tracers and techniques for quantitative standardised analysis will be presented
Dr Karl Herholz
17:10 Chair’s closing remarks
Director, Wolfson Molecular Imaging Centre/ Professor of
Clinical Neuroscience
17:20 End of conference
University of Manchester
5. Registration Form
CNS Clinical Trials
16th - 17th September 2010, London, UK
Angel
For multiple bookings Pentonville Road
Photocopy this form Conf. code VG CNS Clinical Trials
Ci
ty
Ro
ad
Standard Prices 16th - 17th September 2010
Conference only Fee: £1299 VAT: £227.33 Total: £1526.33 Location: SG Conference Centre
B Old Street
Address: Old Street
226-236 City Road
London
EC1V 2TT
City Road
Promotional Literature Distribution
UK
Distribution of your company’s promotional literature to all conference attendees
Fee: £999 VAT: £174.83 Total: £1173.83
Details
How to book
Forename: Surname: Email: conferences@visiongainglobal.com
Web: http://www.visiongain.com/cns-trials
Job Title: Company: UK Office:
Tel: +44(0) 20 7336 6100
Main Switchboard Number: Fax: +44(0) 20 7549 9932
Visiongain Ltd
Address: BSG House
226-236 City Road
London
EC1V 2QY
UK
Country: Postcode:
General information
Venue: Directions: BSG Conference Centre 226 – 236 City Road, London, EC1V 2TT. United
Phone: Fax: Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Travelodge London City
Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503,
Email: http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Signature: Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
I confirm that I have read and agree to the terms and conditions of booking right to charge interest on unpaid invoices.
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
made, whether by post, fax, email or web. There is a no refund policy for cancellations received on
Methods of payment or after one month before the start of the event. Should you decide to cancel after this date, the
full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable
Payment must be made in sterling
to transfer places between conferences and executive briefings. However, if you cannot attend the
By Mail: Complete and return your signed registration form together with your cheque payable conference, you may make a substitution/name change at any time, as long as we are informed in
writing by email, fax or post. Name changes and substitutions must be from the same company or
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK organisation and are not transferable between countries.
By Fax: Complete and fax your signed registration form with your credit card details Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
excluding substitutions/name changes, requested by the customer. This will be charged to the
to +44 (0) 20 7549 9932 customer by credit card prior to the changes being made.
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
By Bank Transfer: expenses, which may be incurred by the customer as a consequence of the event being postponed or
Visiongain Ltd A/C: visiongain Ltd cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
cost of the registration, travel and expenses.
Barclays Bank Sort Code: 20-71-64
Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
Piccadilly Branch Account No: 6038 7118 Protection Act 1988. Your personal information contained in this form may be used to update you on
48 Regent Street Swift Code: BARC GB22
visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
London, W1B 5RA IBAN: GB80 BARC 20716460387118 wish for your details to be amended, suppressed or not passed on to any external third party, please
send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
Please debit my credit card:
EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Access MasterCard Visa American Express Please allow approximately 30 days for your removal or update request to be applied to our database.
Following your removal or update request, you may receive additional pieces of communication from
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
Card number:
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
Expiry Date: incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Security number (last 3 digits on back of credit card): How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Signature:
Unable to attend
Cardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
with your payment. You will receive your copy of the event CD Rom two weeks after the event.
Yes, please send me a copy of the CD for Price£550 VAT:£96.26 Total:£646.26
News updates
Office use only
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/cns-trials